Novozymes As B Stock Last Dividend Paid

NVZMF Stock  USD 59.48  1.98  3.44%   
Novozymes AS B fundamentals help investors to digest information that contributes to Novozymes A/S's financial success or failures. It also enables traders to predict the movement of Novozymes Pink Sheet. The fundamental analysis module provides a way to measure Novozymes A/S's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novozymes A/S pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novozymes AS B Company Last Dividend Paid Analysis

Novozymes A/S's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

 = 

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

Current Novozymes A/S Last Dividend Paid

    
  6.0  
Most of Novozymes A/S's fundamental indicators, such as Last Dividend Paid, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS B is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition

Based on the recorded statements, Novozymes AS B has a Last Dividend Paid of 6.0. This is much higher than that of the Basic Materials sector and significantly higher than that of the Specialty Chemicals industry. The last dividend paid for all United States stocks is notably lower than that of the firm.

Novozymes Last Dividend Paid Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novozymes A/S's direct or indirect competition against its Last Dividend Paid to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novozymes A/S could also be used in its relative valuation, which is a method of valuing Novozymes A/S by comparing valuation metrics of similar companies.
Novozymes is currently under evaluation in last dividend paid category among its peers.

Novozymes Fundamentals

About Novozymes A/S Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novozymes AS B's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes AS B based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Novozymes Pink Sheet

Novozymes A/S financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes A/S security.